Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Last updated: February 11, 2025
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Overall Status: Active - Recruiting

Phase

N/A

Condition

Lymphoma, B-cell

Marginal Zone Lymphoma

Lymphoma

Treatment

N/A

Clinical Study ID

NCT06823960
ZanOs
  • Ages > 18
  • All Genders

Study Summary

Observational, non-interventional, retrospective, multicentre study focusing on efficacy and safety of zanubrutinib in daily clinical practice in patients with relapsed/refractory (R/R) marginal zone lymphoma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Histologically confirmed diagnosis of relapsed/refractory marginal zone lymphoma

  2. Patients who received at least one dose of zanubrutinib under the Named patientprogram (D.M. 7 Sep 2017), between January 2021 and October 2023 3) Age≥18 at startof zanubrutinib therapy. 4) Signature of written informed consent to studyparticipation and personal data processing.

Exclusion

Exclusion Criteria:

  1. relapsed/refractory marginal zone lymphoma patients who received zanubrutinib in aclinical trial context.

Study Design

Total Participants: 59
Study Start date:
December 09, 2024
Estimated Completion Date:
June 30, 2025

Study Description

Due to the rarity of the condition and the novelty of its application, the study is intended to be exploratory, with the aim of providing interim evidence on which to plan future studies in larger populations. Data will be collected from the start of therapy until 6 months after the end of therapy, when applicable.

Connect with a study center

  • Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS

    Meldola, Forlì Cesena 47017
    Italy

    Active - Recruiting

  • AOU SS Antonio e Biagio e Cesare Arrigo

    Alessandria, 15121
    Italy

    Site Not Available

  • IRCCS-AOU di Bologna

    Bologna, 40138
    Italy

    Site Not Available

  • P.O. Garibaldi-Nesima_UOC Ematologia

    Catania, 95122
    Italy

    Site Not Available

  • AO di Cosenza, P.O. "Annunziata" - UOC di Ematologia

    Cosenza, 87100
    Italy

    Site Not Available

  • AOU di Ferrara_ UO di Ematologia - Dipartimento di Oncologia e Medicine Specialistiche

    Ferrara, 44124
    Italy

    Site Not Available

  • ASST Grande Ospedale Metropolitano Niguarda _ UOC Ematologia

    Milano, 20162
    Italy

    Site Not Available

  • Istituto Clinico Humanitas IRCCS - UO Ematologia

    Milano, 20089
    Italy

    Site Not Available

  • IOV - Istituto Oncologico Veneto - IRCCS _UOC Oncologia1

    Padova, 35128
    Italy

    Site Not Available

  • Ospedali Riuniti Villa Sofia - Cervello _ UO di Ematologia ad Indirizzo Oncologico

    Palermo, 90146
    Italy

    Site Not Available

  • Ospedale Santa Maria delle Croci- OU Ematologia di Ravenna

    Ravenna, 48121
    Italy

    Site Not Available

  • Fondazione PTV Policlinico Tor Vergata- U.O.C. Patologie Linfoproliferative

    Roma, 00133
    Italy

    Site Not Available

  • AOU Città della Salute e della Scienza, "Le Molinette" - Divisione di Ematologia

    Torino, 10126
    Italy

    Site Not Available

  • Ospedale Ca' Foncello, Azienda ULSS n. 2 Marca trevigiana - UOC Ematologia Dipartimento di Medicina

    Treviso, 31100
    Italy

    Site Not Available

  • Azienda sanitaria universitaria Giuliano Isontina (ASU GI) - Ospedale Maggiore- SC (UCO) Ematologia

    Trieste, 34128
    Italy

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.